▶ 調査レポート

ファーマコゲノミクス技術(セラノスティクス・CDx)のグローバル市場インサイト・予測(~2028年)

• 英文タイトル:Global Pharmacogenomics Technology (Theranostics & CDx) Market Insights and Forecast to 2028

QYResearchが調査・発行した産業分析レポートです。ファーマコゲノミクス技術(セラノスティクス・CDx)のグローバル市場インサイト・予測(~2028年) / Global Pharmacogenomics Technology (Theranostics & CDx) Market Insights and Forecast to 2028 / QY2203B05259資料のイメージです。• レポートコード:QY2203B05259
• 出版社/出版日:QYResearch / 2022年3月11日
• レポート形態:英文、PDF、106ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥646,800 (USD4,900)▷ お問い合わせ
  Multi User¥970,200 (USD7,350)▷ お問い合わせ
  Enterprise License¥1,293,600 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
新型コロナウイルス感染症のパンデミックにより、世界のファーマコゲノミクス技術(セラノスティクス・CDx)の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にファーマコゲノミクス技術(セラノスティクス・CDx)の世界市場のxxx%を占める「機器」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「腫瘍」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
中国のファーマコゲノミクス技術(セラノスティクス・CDx)の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのファーマコゲノミクス技術(セラノスティクス・CDx)市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパのファーマコゲノミクス技術(セラノスティクス・CDx)市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

ファーマコゲノミクス技術(セラノスティクス・CDx)のグローバル主要メーカーには、Illumina、Roche、Agilent、Abbott、Thermofisher、Qiagen、Guardant Health、MGI Tech Co., Ltd.、Amoydx Biology、Genomicsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

ファーマコゲノミクス技術(セラノスティクス・CDx)市場は、種類と用途によって区分されます。世界のファーマコゲノミクス技術(セラノスティクス・CDx)市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
機器、試薬・消耗品、その他

【用途別セグメント】
腫瘍、糖尿病、精神疾患、循環器疾患、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- ファーマコゲノミクス技術(セラノスティクス・CDx)製品概要
- 種類別市場(機器、試薬・消耗品、その他)
- 用途別市場(腫瘍、糖尿病、精神疾患、循環器疾患、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界のファーマコゲノミクス技術(セラノスティクス・CDx)販売量予測2017-2028
- 世界のファーマコゲノミクス技術(セラノスティクス・CDx)売上予測2017-2028
- ファーマコゲノミクス技術(セラノスティクス・CDx)の地域別販売量
- ファーマコゲノミクス技術(セラノスティクス・CDx)の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別ファーマコゲノミクス技術(セラノスティクス・CDx)販売量
- 主要メーカー別ファーマコゲノミクス技術(セラノスティクス・CDx)売上
- 主要メーカー別ファーマコゲノミクス技術(セラノスティクス・CDx)価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(機器、試薬・消耗品、その他)
- ファーマコゲノミクス技術(セラノスティクス・CDx)の種類別販売量
- ファーマコゲノミクス技術(セラノスティクス・CDx)の種類別売上
- ファーマコゲノミクス技術(セラノスティクス・CDx)の種類別価格
・用途別市場規模(腫瘍、糖尿病、精神疾患、循環器疾患、その他)
- ファーマコゲノミクス技術(セラノスティクス・CDx)の用途別販売量
- ファーマコゲノミクス技術(セラノスティクス・CDx)の用途別売上
- ファーマコゲノミクス技術(セラノスティクス・CDx)の用途別価格
・北米市場
- 北米のファーマコゲノミクス技術(セラノスティクス・CDx)市場規模(種類別、用途別)
- 主要国別のファーマコゲノミクス技術(セラノスティクス・CDx)市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパのファーマコゲノミクス技術(セラノスティクス・CDx)市場規模(種類別、用途別)
- 主要国別のファーマコゲノミクス技術(セラノスティクス・CDx)市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋のファーマコゲノミクス技術(セラノスティクス・CDx)市場規模(種類別、用途別)
- 主要国別のファーマコゲノミクス技術(セラノスティクス・CDx)市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米のファーマコゲノミクス技術(セラノスティクス・CDx)市場規模(種類別、用途別)
- 主要国別のファーマコゲノミクス技術(セラノスティクス・CDx)市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカのファーマコゲノミクス技術(セラノスティクス・CDx)市場規模(種類別、用途別)
- 主要国別のファーマコゲノミクス技術(セラノスティクス・CDx)市場規模(トルコ、サウジアラビア)
・企業情報
Illumina、Roche、Agilent、Abbott、Thermofisher、Qiagen、Guardant Health、MGI Tech Co., Ltd.、Amoydx Biology、Genomics
・産業チェーン及び販売チャネル分析
- ファーマコゲノミクス技術(セラノスティクス・CDx)の産業チェーン分析
- ファーマコゲノミクス技術(セラノスティクス・CDx)の原材料
- ファーマコゲノミクス技術(セラノスティクス・CDx)の生産プロセス
- ファーマコゲノミクス技術(セラノスティクス・CDx)の販売及びマーケティング
- ファーマコゲノミクス技術(セラノスティクス・CDx)の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- ファーマコゲノミクス技術(セラノスティクス・CDx)の産業動向
- ファーマコゲノミクス技術(セラノスティクス・CDx)のマーケットドライバー
- ファーマコゲノミクス技術(セラノスティクス・CDx)の課題
- ファーマコゲノミクス技術(セラノスティクス・CDx)の阻害要因
・主な調査結果

Market Analysis and Insights: Global Pharmacogenomics Technology (Theranostics & CDx) Market
The global Pharmacogenomics Technology (Theranostics & CDx) market size is projected to reach US$ 25330 million by 2028, from US$ 9591.9 million in 2021, at a CAGR of 14.7% during 2022-2028.
Pharmacogenomics Technology (Theranostics & CDx) manufacturers include Illumina, Roche and Agilent etc. The top 3 company holds a share of more than 50%. North America takes up the largest sales market, with a share of more than 40%, followed by Europe and China, with the share of about 30% and 10% respectively.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Pharmacogenomics Technology (Theranostics & CDx) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Pharmacogenomics Technology (Theranostics & CDx) market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Pharmacogenomics Technology (Theranostics & CDx) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Pharmacogenomics Technology (Theranostics & CDx) market.
Global Pharmacogenomics Technology (Theranostics & CDx) Scope and Market Size
Pharmacogenomics Technology (Theranostics & CDx) market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Pharmacogenomics Technology (Theranostics & CDx) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Instrument
Reagents and Consumables
Others
Segment by Application
Tumor
Diabetes
Mental Diseases
Cardiovascular Diseases
Others
By Company
Illumina
Roche
Agilent
Abbott
Thermofisher
Qiagen
Guardant Health
MGI Tech Co., Ltd.
Amoydx Biology
Genomics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Instrument
1.2.3 Reagents and Consumables
1.2.4 Others
1.3 Market by Application
1.3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Mental Diseases
1.3.5 Cardiovascular Diseases
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Perspective (2017-2028)
2.2 Pharmacogenomics Technology (Theranostics & CDx) Growth Trends by Region
2.2.1 Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Region (2017-2022)
2.2.3 Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (2023-2028)
2.3 Pharmacogenomics Technology (Theranostics & CDx) Market Dynamics
2.3.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Trends
2.3.2 Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
2.3.3 Pharmacogenomics Technology (Theranostics & CDx) Market Challenges
2.3.4 Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue
3.1.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue (2017-2022)
3.1.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Players (2017-2022)
3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmacogenomics Technology (Theranostics & CDx) Revenue
3.4 Global Pharmacogenomics Technology (Theranostics & CDx) Market Concentration Ratio
3.4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmacogenomics Technology (Theranostics & CDx) Revenue in 2021
3.5 Pharmacogenomics Technology (Theranostics & CDx) Key Players Head office and Area Served
3.6 Key Players Pharmacogenomics Technology (Theranostics & CDx) Product Solution and Service
3.7 Date of Enter into Pharmacogenomics Technology (Theranostics & CDx) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmacogenomics Technology (Theranostics & CDx) Breakdown Data by Type
4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Type (2017-2022)
4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (2023-2028)
5 Pharmacogenomics Technology (Theranostics & CDx) Breakdown Data by Application
5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Application (2017-2022)
5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2017-2028)
6.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
6.2.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022)
6.2.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2023-2028)
6.2.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2017-2028)
6.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
6.3.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022)
6.3.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2028)
6.3.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2017-2028)
6.4 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
6.4.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2017-2022)
6.4.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size (2017-2028)
7.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
7.2.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022)
7.2.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2023-2028)
7.2.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2017-2028)
7.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
7.3.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022)
7.3.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2028)
7.3.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2017-2028)
7.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
7.4.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2017-2022)
7.4.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size (2017-2028)
8.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
8.2.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2017-2028)
8.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
8.3.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2017-2028)
8.4 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region
8.4.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2017-2028)
9.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
9.2.1 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022)
9.2.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2023-2028)
9.2.3 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2017-2028)
9.3 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
9.3.1 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022)
9.3.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2028)
9.3.3 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2017-2028)
9.4 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
9.4.1 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2017-2022)
9.4.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size (2017-2028)
10.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type
10.2.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type (2017-2028)
10.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application
10.3.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application (2017-2028)
10.4 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country
10.4.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Illumina
11.1.1 Illumina Company Details
11.1.2 Illumina Business Overview
11.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.1.4 Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.1.5 Illumina Recent Developments
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.2.4 Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.2.5 Roche Recent Developments
11.3 Agilent
11.3.1 Agilent Company Details
11.3.2 Agilent Business Overview
11.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.3.4 Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.3.5 Agilent Recent Developments
11.4 Abbott
11.4.1 Abbott Company Details
11.4.2 Abbott Business Overview
11.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.4.4 Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.4.5 Abbott Recent Developments
11.5 Thermofisher
11.5.1 Thermofisher Company Details
11.5.2 Thermofisher Business Overview
11.5.3 Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.5.4 Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.5.5 Thermofisher Recent Developments
11.6 Qiagen
11.6.1 Qiagen Company Details
11.6.2 Qiagen Business Overview
11.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.6.4 Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.6.5 Qiagen Recent Developments
11.7 Guardant Health
11.7.1 Guardant Health Company Details
11.7.2 Guardant Health Business Overview
11.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.7.4 Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.7.5 Guardant Health Recent Developments
11.8 MGI Tech Co., Ltd.
11.8.1 MGI Tech Co., Ltd. Company Details
11.8.2 MGI Tech Co., Ltd. Business Overview
11.8.3 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.8.4 MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.8.5 MGI Tech Co., Ltd. Recent Developments
11.9 Amoydx Biology
11.9.1 Amoydx Biology Company Details
11.9.2 Amoydx Biology Business Overview
11.9.3 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.9.4 Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.9.5 Amoydx Biology Recent Developments
11.10 Genomics
11.10.1 Genomics Company Details
11.10.2 Genomics Business Overview
11.10.3 Genomics Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.10.4 Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
11.10.5 Genomics Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Instrument
Table 3. Key Players of Reagents and Consumables
Table 4. Key Players of Others
Table 5. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 6. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2017-2022)
Table 9. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2023-2028)
Table 11. Pharmacogenomics Technology (Theranostics & CDx) Market Trends
Table 12. Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
Table 13. Pharmacogenomics Technology (Theranostics & CDx) Market Challenges
Table 14. Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
Table 15. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Players (2017-2022)
Table 17. Global Top Pharmacogenomics Technology (Theranostics & CDx) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics Technology (Theranostics & CDx) as of 2021)
Table 18. Ranking of Global Top Pharmacogenomics Technology (Theranostics & CDx) Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Pharmacogenomics Technology (Theranostics & CDx) Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Pharmacogenomics Technology (Theranostics & CDx) Product Solution and Service
Table 22. Date of Enter into Pharmacogenomics Technology (Theranostics & CDx) Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2017-2022)
Table 26. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2023-2028)
Table 28. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2017-2022)
Table 30. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application (2023-2028)
Table 32. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022) & (US$ Million)
Table 33. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2023-2028) & (US$ Million)
Table 34. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022) & (US$ Million)
Table 35. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2028) & (US$ Million)
Table 36. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2017-2022) & (US$ Million)
Table 37. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2023-2028) & (US$ Million)
Table 38. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022) & (US$ Million)
Table 39. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2023-2028) & (US$ Million)
Table 40. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022) & (US$ Million)
Table 41. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2028) & (US$ Million)
Table 42. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2017-2022) & (US$ Million)
Table 43. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2023-2028) & (US$ Million)
Table 44. Asia Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022) & (US$ Million)
Table 45. Asia Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2023-2028) & (US$ Million)
Table 46. Asia Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022) & (US$ Million)
Table 47. Asia Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2028) & (US$ Million)
Table 48. Asia Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2017-2022) & (US$ Million)
Table 49. Asia Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2023-2028) & (US$ Million)
Table 50. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022) & (US$ Million)
Table 51. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2023-2028) & (US$ Million)
Table 52. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022) & (US$ Million)
Table 53. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2028) & (US$ Million)
Table 54. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2017-2022) & (US$ Million)
Table 55. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2023-2028) & (US$ Million)
Table 56. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2023-2028) & (US$ Million)
Table 62. Illumina Company Details
Table 63. Illumina Business Overview
Table 64. Illumina Pharmacogenomics Technology (Theranostics & CDx) Product
Table 65. Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 66. Illumina Recent Developments
Table 67. Roche Company Details
Table 68. Roche Business Overview
Table 69. Roche Pharmacogenomics Technology (Theranostics & CDx) Product
Table 70. Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 71. Roche Recent Developments
Table 72. Agilent Company Details
Table 73. Agilent Business Overview
Table 74. Agilent Pharmacogenomics Technology (Theranostics & CDx) Product
Table 75. Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 76. Agilent Recent Developments
Table 77. Abbott Company Details
Table 78. Abbott Business Overview
Table 79. Abbott Pharmacogenomics Technology (Theranostics & CDx) Product
Table 80. Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 81. Abbott Recent Developments
Table 82. Thermofisher Company Details
Table 83. Thermofisher Business Overview
Table 84. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Product
Table 85. Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 86. Thermofisher Recent Developments
Table 87. Qiagen Company Details
Table 88. Qiagen Business Overview
Table 89. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product
Table 90. Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 91. Qiagen Recent Developments
Table 92. Guardant Health Company Details
Table 93. Guardant Health Business Overview
Table 94. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product
Table 95. Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 96. Guardant Health Recent Developments
Table 97. MGI Tech Co., Ltd. Company Details
Table 98. MGI Tech Co., Ltd. Business Overview
Table 99. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Product
Table 100. MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 101. MGI Tech Co., Ltd. Recent Developments
Table 102. Amoydx Biology Company Details
Table 103. Amoydx Biology Business Overview
Table 104. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Product
Table 105. Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 106. Amoydx Biology Recent Developments
Table 107. Genomics Company Details
Table 108. Genomics Business Overview
Table 109. Genomics Pharmacogenomics Technology (Theranostics & CDx) Product
Table 110. Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US$ Million)
Table 111. Genomics Recent Developments
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type: 2021 VS 2028
Figure 2. Instrument Features
Figure 3. Reagents and Consumables Features
Figure 4. Others Features
Figure 5. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application: 2021 VS 2028
Figure 6. Tumor Case Studies
Figure 7. Diabetes Case Studies
Figure 8. Mental Diseases Case Studies
Figure 9. Cardiovascular Diseases Case Studies
Figure 10. Others Case Studies
Figure 11. Pharmacogenomics Technology (Theranostics & CDx) Report Years Considered
Figure 12. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 13. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region: 2021 VS 2028
Figure 15. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Players in 2021
Figure 16. Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics Technology (Theranostics & CDx) as of 2021)
Figure 17. The Top 10 and 5 Players Market Share by Pharmacogenomics Technology (Theranostics & CDx) Revenue in 2021
Figure 18. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY (2017-2028) & (US$ Million)
Figure 19. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Type (2017-2028)
Figure 20. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application (2017-2028)
Figure 21. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Country (2017-2028)
Figure 22. United States Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Canada Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY (2017-2028) & (US$ Million)
Figure 25. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Type (2017-2028)
Figure 26. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application (2017-2028)
Figure 27. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Country (2017-2028)
Figure 28. Germany Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. France Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. U.K. Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Italy Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Russia Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Nordic Countries Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY (2017-2028) & (US$ Million)
Figure 35. Asia Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Type (2017-2028)
Figure 36. Asia Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application (2017-2028)
Figure 37. Asia Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Region (2017-2028)
Figure 38. China Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Japan Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. South Korea Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. India Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Australia Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY (2017-2028) & (US$ Million)
Figure 45. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Type (2017-2028)
Figure 46. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application (2017-2028)
Figure 47. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Country (2017-2028)
Figure 48. Mexico Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Brazil Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 50. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY (2017-2028) & (US$ Million)
Figure 51. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Type (2017-2028)
Figure 52. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Market Share by Application (2017-2028)
Figure 53. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Share by Country (2017-2028)
Figure 54. Turkey Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. UAE Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 57. Illumina Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
Figure 58. Roche Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
Figure 59. Agilent Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
Figure 60. Abbott Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
Figure 61. Thermofisher Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
Figure 62. Qiagen Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
Figure 63. Guardant Health Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
Figure 64. MGI Tech Co., Ltd. Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
Figure 65. Amoydx Biology Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
Figure 66. Genomics Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed